Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

摘要: Purpose: There is increasing evidence that the chimeric monoclonal antibody G250 (cG250) can be internalized by antigen-expressing renal cell carcinoma (RCC) cells. Thus, accumulation in tumors of cG250 labeled with residualizing radionuclides might higher than nonresidualizing 131I-cG250. Here, we present a study comparing intrapatiently 131I-cG250 and 111In-cG250 RCC metastases. Experimental Design: Five patients were i.v. injected 222 MBq 111In-ITC-DTPA-cG250 on days 0 4, respectively. Directly 4 after injection both preparations, whole body gamma camera images acquired. The scintigraphic analyzed visually quantitatively. radioactivity tissues was calculated expressed as percentage dose organs or dose/g For latter, tumor:blood ratios also calculated. Twenty-five metastases completely. Results: At postinjection, revealed more metastatic lesions (n = 47) 30). Quantitative analysis showed activities 20 25 lesions. mean overall half-life preparations plasma similar. Conclusions:111In-ITC-DTPA-cG250 outperformed for visualization lesions, not just because superior characteristics 111In, but importantly, obtained. caused internalization subsequent intracellular retention radiolabel, implying future radioimmunotherapy trials patients, use radionuclide should considered.